Antigen binding molecules and methods of use thereof

Abstract

Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GGGS (SEQ ID NO: 1), GGGGS (SEQ ID NO: 46) and related sequences are provided. The antigen binding molecules may be used in the methods provided herein.

1 . An isolated antigen binding molecule that specifically binds to a polypeptide comprising the amino acid sequence GGGS (SEQ ID NO: 1). 
     
     
         2 . The isolated antigen binding molecule of  claim 1 , wherein the polypeptide is a chimeric antigen receptor (CAR). 
     
     
         3 . The antigen binding molecule of  claim 1 , wherein the antigen binding molecule is an antibody. 
     
     
         4 . The antigen binding molecule of  claim 1 , wherein the antigen binding molecule comprises:
 (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 26;   (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 27;   (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 19;   (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 8;   (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 9; and   (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 10.   
     
     
         5 . The antigen binding molecule of  claim 4 , wherein the antigen binding molecule comprises:
 (a) a VH comprising the amino acid sequence of SEQ ID NO: 2; and   (b) a VL comprising the amino acid sequence of SEQ ID NO: 3.   
     
     
         6 . The antigen binding molecule of  claim 1 , wherein the antigen binding molecule comprises:
 (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 28;   (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 29;   (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 22;   (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 11;   (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 12; and   (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 13.   
     
     
         7 . The antigen binding molecule of  claim 6 , wherein the antigen binding molecule comprises:
 (a) a VH comprising the amino acid sequence of SEQ ID NO: 4; and   (b) a VL comprising the amino acid sequence of SEQ ID NO: 5.   
     
     
         8 . The antigen binding molecule of  claim 1 , wherein the antigen binding molecule comprises:
 (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 30;   (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 31;   (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 25;   (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 14;   (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 15; and   (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 16.   
     
     
         9 . The antigen binding molecule of  claim 8 , wherein the antigen binding molecule comprises:
 (a) a VH comprising the amino acid sequence of SEQ ID NO: 6; and   (b) a VL comprising the amino acid sequence of SEQ ID NO: 7.   
     
     
         10 . The antigen binding molecule of  claim 1 , comprising a detectable label, wherein the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten. 
     
     
         11 . The antigen binding molecule of  claim 10 , wherein the fluorescent label is selected from the group consisting of an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, BD, R-Phycoerythrin (PE), PECy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean, mCFP, mTurquoise2, ECFP, CyPet, GFP (Y66W mutation), mKeima-Red, TagCFP, AmCyanl, mTFP1, GFP (S65A mutation), Midorishi Cyan, Wild Type GFP, GFP (S65C mutation), TurboGFP, TagGFP, GFP (S65L mutation), Emerald, GFP (S65T mutation), EGFP, Azami Green, ZsGreenl, TagYFP, EYFP, Topaz, Venus, mCitrine, YPet, TurboYFP, ZsYellowl, Kusabira Orange, mOrange, Allophycocyanin (APC), mKO, TurboRFP, tdTomato, TagRFP, DsRed monomer, DsRed2 (“RFP”), mStrawberry, TurboFP602, AsRed2, mRFP1, J-Red, R-phycoerythrin (RPE), Bphycoerythrin (BPE), mCherry, HcRed1, Katusha, P3, Peridinin Chlorophyll (PerCP), mKate (TagFP635), TurboFP635, mPlum, and mRaspberry. 
     
     
         12 . A composition comprising the antigen binding molecule of  claim 1 .